Braidwell’s MoonLake Immunotherapeutics MLTX Stock Holding History

Braidwell’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-381,120	Closed	-$4M	–	90
2022 Q4	$4M	Buy	+381,120	New	+$3.39M	0.13%	85

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Braidwell's MLTX Position: Q1 2023 in Review

Braidwell sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2023, closing a stake of 381,120 shares — an estimated $4M sold.

Braidwell first reported a position in MLTX in Q4 2022 and held it in 1 quarter. The position peaked at $4M in Q4 2022. 43 funds tracked by Wall St. Rank hold MLTX as of Q1 2023.

Braidwell reported no remaining MoonLake Immunotherapeutics position as of Q1 2023 after selling out during the quarter.
Braidwell sold 381,120 MoonLake Immunotherapeutics shares in Q1 2023, an estimated $4M.
Braidwell first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 1 quarter.
Braidwell's MoonLake Immunotherapeutics position peaked at $4M in Q4 2022.
43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2023.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.